Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Inflamm Bowel Dis ; 10(3): 274-7, 2004 May.
Article in English | MEDLINE | ID: mdl-15290924

ABSTRACT

Infliximab (Remicade), a chimeric monoclonal antibody to tumor necrosis factor-alpha (anti-TNF-alpha), is being used with increasing frequency in the treatment of Crohn's disease. Infliximab's safety profile to date has been good with reported adverse events being mild to moderate. We report a case of diffuse alveolar hemorrhage after the second infliximab infusion in a patient with Crohn's disease. The mechanism by which infliximab may have caused the observed pulmonary insult remains unknown. Physicians should be aware of the possible association between infliximab treatment and the development of alveolar hemorrhage. Future cases should be reported.


Subject(s)
Antibodies, Monoclonal/adverse effects , Crohn Disease/drug therapy , Gastrointestinal Agents/adverse effects , Hemorrhage/chemically induced , Pulmonary Alveoli , Adult , Antibodies, Monoclonal/therapeutic use , Female , Gastrointestinal Agents/therapeutic use , Humans , Infliximab , Pneumonia/chemically induced , Pneumonia/diagnosis , Pulmonary Alveoli/pathology , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...